OSE Pharma SA (OSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OSE Pharma SA (OSE) has a cash flow conversion efficiency ratio of -0.355x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.98 Million ≈ $-21.02 Million USD) by net assets (€50.60 Million ≈ $59.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OSE Pharma SA (OSE) total market value for the company's overall valuation and market capitalisation.
OSE Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how OSE Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OSE Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSE Pharma SA ranked by their cash flow conversion efficiency. Explore earnings quality score of OSE Pharma SA to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
L.P.N. Development Public Company Limited
BK:LPN
|
0.018x |
|
Grong Sparebank
OL:GRONG
|
N/A |
|
NS Co. Ltd
KQ:217820
|
0.071x |
|
Panin Sekuritas Tbk
JK:PANS
|
0.079x |
|
Soonest Express Co Ltd
TWO:2643
|
0.232x |
|
Universal Inc
TW:1325
|
-0.009x |
|
Johnson Chemical Pharmaceutical Works Co Ltd
TWO:4747
|
0.008x |
|
Thitikorn Public Company Limited
BK:TK
|
-0.034x |
Annual Cash Flow Conversion Efficiency for OSE Pharma SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of OSE Pharma SA from 2012 to 2024. View latest OSE Pharma SA stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €63.81 Million ≈ $74.60 Million |
€48.44 Million ≈ $56.63 Million |
0.759x | +188.24% |
| 2023-12-31 | €22.98 Million ≈ $26.86 Million |
€-19.76 Million ≈ $-23.11 Million |
-0.860x | -53.40% |
| 2022-12-31 | €32.55 Million ≈ $38.05 Million |
€-18.25 Million ≈ $-21.34 Million |
-0.561x | -168.75% |
| 2021-12-31 | €47.53 Million ≈ $55.57 Million |
€-9.92 Million ≈ $-11.60 Million |
-0.209x | +34.64% |
| 2020-12-31 | €61.24 Million ≈ $71.59 Million |
€-19.55 Million ≈ $-22.86 Million |
-0.319x | -308.16% |
| 2019-12-31 | €58.49 Million ≈ $68.38 Million |
€8.97 Million ≈ $10.49 Million |
0.153x | +779.40% |
| 2018-12-31 | €61.75 Million ≈ $72.20 Million |
€1.08 Million ≈ $1.26 Million |
0.017x | +112.09% |
| 2017-12-31 | €55.45 Million ≈ $64.82 Million |
€-8.00 Million ≈ $-9.35 Million |
-0.144x | -1460.42% |
| 2016-12-31 | €64.53 Million ≈ $75.44 Million |
€684.00K ≈ $799.67K |
0.011x | +103.33% |
| 2015-12-31 | €14.48 Million ≈ $16.92 Million |
€-4.61 Million ≈ $-5.39 Million |
-0.319x | -113.21% |
| 2014-12-31 | €-803.00K ≈ $-938.79K |
€-1.94 Million ≈ $-2.26 Million |
2.412x | +783.11% |
| 2013-12-31 | €-864.00K ≈ $-1.01 Million |
€-236.00K ≈ $-275.91K |
0.273x | -87.59% |
| 2012-12-31 | €-633.00K ≈ $-740.04K |
€-1.39 Million ≈ $-1.63 Million |
2.201x | -- |
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more